BioCentury
ARTICLE | Company News

vivoPharm, Protea Biosciences deal

May 11, 2015 7:00 AM UTC

Protea will acquire cancer services company vivoPharm for $5.5 million in cash and $5.7 million in newly issued convertible preferred stock. Protea said it will combine its mass spectrometry system wi...